Original ContributionsDRD2 Genotypic and Haplotype Variation Is Associated With Improvements in Negative Symptoms After 6 Weeks’ Amisulpride TreatmentKang, Seung-Gul MD, PhD*; Na, Kyoung-Sae MD*; Lee, Heon-Jeong MD, PhD†; Chee, Ik-Seung MD, PhD‡; Lee, Kwanghun MD, PhD§; Lee, Jonghun MD, PhD║Author Information From the *Department of Psychiatry, Gil Medical Center, Gachon University, School of Medicine, Incheon; †Department of Psychiatry, Korea University College of Medicine, Seoul; ‡Department of Psychiatry, School of Medicine, Institute of Brain Research, Chungnam National University, Daejeon; §Department of Psychiatry, Dongguk University College of Medicine, Gyeongju; and ║Department of Psychiatry, Catholic University of Daegu School of Medicine, Daegu, South Korea. Received August 13, 2014; accepted after revision January 2, 2015. Reprints: Jonghun Lee, MD, PhD, Department of Psychiatry, Catholic University of Daegu School of Medicine, 3056–6 Daemyung-4 Dong, Nam-Gu, Daegu City, 705–718, South Korea (e-mail: [email protected]). Supported by a grant from Sanofi Aventis Korea Co, Ltd. Supplemental digital contents are available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.psychopharmacology.com). Journal of Clinical Psychopharmacology: April 2015 - Volume 35 - Issue 2 - p 158-162 doi: 10.1097/JCP.0000000000000294 Buy SDC Metrics Abstract The aim of this study was to identify the association between the rs1079597 and rs1800497 genetic polymorphisms of the gene encoding the dopamine D2 receptor (DRD2) protein and the treatment response to the selective dopamine receptor antagonist amisulpride. After 6 weeks of treatment with amisulpride, 125 schizophrenia patients were interviewed based on the Positive and Negative Syndrome Scale and the Clinical Global Impression-Severity Scale. Genotyping for rs1079597 and rs1800497 was performed using the TaqMan single nucleotide polymorphism genotyping assay. There were significant differences in the genotype frequency of the recessive model (χ2 = 5.73, P = 0.017) and allele frequency (χ2 = 5.16, P = 0.023) of rs1079597 between the responders and nonresponders based on the Positive and Negative Syndrome Scale negative symptoms scores. There was no significant finding in this regard for the rs1800497 polymorphism. The T-C and C-C haplotype of rs1079597-rs1800497 were associated with the negative symptom treatment response to amisulpride after permutation test. To the best of our knowledge, this is the first report of the positive finding in the association study between rs1079597 polymorphism and the treatment response to amisulpride in schizophrenic patients. A larger scale study involving more single nucleotide polymorphisms of DRD2 will progress the research into the pharmacogenetics of the treatment response to amisulpride. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.